Elicio Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
ELTX$1.61-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (unaudited)
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $11,853 | $12,894 |
| Restricted cash, current | 665 | 722 |
| Prepaid expenses and other current assets | 1,612 | 2,732 |
| Total current assets | 14,130 | 16,348 |
| Property and equipment, net | 635 | 717 |
| Operating lease, right-of-use assets | 6,354 | 6,563 |
| Restricted cash, noncurrent | 688 | 685 |
| Other long-term prepaid assets | 2,673 | 2,833 |
| Total assets | $24,480 | $27,146 |
| Liabilities and stockholders’ equity | ||
| Current liabilities | ||
| Accounts payable | $1,105 | $4,369 |
| Accrued expenses | 3,324 | 3,757 |
| Deferred research obligation | 627 | 694 |
| Operating lease liability, current | 881 | 910 |
| Unvested option exercise liability, current | 14 | 25 |
| Total current liabilities | 5,951 | 9,755 |
| Warrant liability | 7,868 | 11 |
| Operating lease liability, noncurrent | 5,791 | 6,007 |
| Total liabilities | 19,610 | 15,773 |
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.01 par value; 300,000,000 shares authorized at March 31, 2024 and December 31, 2023; 10,234,444 shares and 9,618,178 shares issued at March 31, 2024 and December 31, 2023, respectively; 10,219,989 and 9,603,723 outstanding as of March 31, 2024 and December 31, 2023, respectively | 102 | 96 |
| Treasury stock, at cost, 14,455 shares outstanding as of March 31, 2024 and December 31, 2023 | (150) | (150) |
| Additional paid-in capital | 159,218 | 153,827 |
| Accumulated other comprehensive loss | (270) | (197) |
| Accumulated deficit | (154,030) | (142,203) |
| Total stockholders' equity | 4,870 | 11,373 |
| Total liabilities and stockholders' equity | $24,480 | $27,146 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.